Disorders of Sex Development

Genetic Diagnosis of Endocrine Disorders

Volumn , Issue , 2010, Pages 227-243

  Arboleda, Valerie A ^a   Fleming, Alice A ^a   Vilain, Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864403968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374430-2.00021-3     Document Type: Chapter

References (111)

1. Lee A., et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006, 118(2):e488-e500.
2. Knower K.C., Kelly S., Harley V.R. Turning on the male - SRY, SOX9 and sex determination in mammals. Cytogenet. Genome. Res. 2003, 101(3-4):185-198.
3. McElreavey K., et al. XY sex reversal associated with a deletion 5' to the SRY "HMG box" in the testis-determining region. Proc. Natl. Acad. Sci. USA 1992, 89(22):11016-11020.
4. Uehara S., et al. Complete XY gonadal dysgenesis and aspects of the SRY genotype and gonadal tumor formation. J. Hum. Genet. 2002, 47(6):279-284.
5. Assumpcao J.G., et al. Novel mutations affecting SRY DNA-binding activity: the HMG box N65H associated with 46,XY pure gonadal dysgenesis and the familial non-HMG box R30I associated with variable phenotypes. J. Mol. Med. 2002, 80(12):782-790.
6. Sekido R., Lovell-Badge R. Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer. Nature 2008, 453(7197):930-934.
7. Uehara S., et al. SRY mutation and tumor formation on the gonads of XY pure gonadal dysgenesis patients. Cancer Genet. Cytogenet. 1999, 113(1):78-84.
8. Li B., et al. Human sex reversal due to impaired nuclear localization of SRY. J. Biol. Chem. 2001, 276(49):46480-46484.
9. Mitchell C.L., Harley V.R Biochemical defects in eight SRY missense mutations causing XY gonadal dysgenesis. Mol. Genet. Metab. 2002, 77(3):217-225.
10. Kohler B., et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum. Mutat. 2008, 29(1):59-64.
11. Ozisik G., Achermann J.C., Jameson J.L. The role of SF1 in adrenal and reproductive function: insight from naturally occurring mutations in humans. Mol. Genet. Metab. 2002, 76(2):85-91.
12. Tremblay J.J., Viger R.S A mutated form of steroidogenic factor 1 (SF-1 G35E) that causes sex reversal in humans fails to synergize with transcription factor GATA-4. J. Biol. Chem. 2003, 278(43):42637-42642.
13. Capel B. Sex in the 90s: SRY and the switch to the male pathway. Annu. Rev. Physiol. 1998, 60:497-523.
14. Saylam K., Simon P. WT1 gene mutation responsible for male sex reversal and renal failure: the Frasier syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003, 110(1):111-113.
15. Domenice S., et al. Mutations in the SRY, DAX1, SF1 and WNT4 genes in Brazilian sex-reversed patients. Braz. J. Med. Biol. Res. 2004, 37(1):145-150.
16. Migeon C.J., Wisniewski A.B Human sex differentiation and its abnormalities. Best. Pract. Res. Clin. Obstet. Gynaecol. 2003, 17(1):1-18.
17. Reddy K.S., Sulcova V. Pathogenetics of 45,X/46,XY gonadal mosaicism. Cytogenet. Cell Genet. 1998, 82(1-2):52-57.
18. Rosenberg C., et al. Phenotypic spectrum of 45,X/46,XY individuals. Am. J. Med. Genet. 1987, 27(3):553-559.
19. Knudtzon J., Aarskog D. 45,X/46,XY mosaicism. A clinical review and report of ten cases. Eur J Pediatr 1987, 146(3):266-271.
20. McElreavey K., et al. A minority of 46,XX true hermaphrodites are positive for the Y-DNA sequence including SRY. Hum. Genet. 1992, 90(1-2):121-125.
21. Queipo G., et al. Molecular analysis in true hermaphroditism: demonstration of low-level hidden mosaicism for Y-derived sequences in 46,XX cases. Hum. Genet. 2002, 111(3):278-283.
22. Zenteno-Ruiz J.C., Kofman-Alfaro S., Mendez J. 46,XX sex reversal. Arch. Med. Res. 2001, 32(6):559-566.
23. Bouayed Abdelmoula N., et al. Skewed X-chromosome inactivation pattern in SRY positive XX maleness: a case report and review of literature. Ann. Genet. 2003, 46(1):11-18.
24. Kusz K., et al. Incomplete masculinisation of XX subjects carrying the SRY gene on an inactive X chromosome. J. Med. Genet. 1999, 36(6):452-456.
25. Tomaselli S., et al. Syndromic true hermaphroditism due to an R-spondin1 (RSPO1) homozygous mutation. Hum. Mutat. 2008, 29(2):220-226.
26. Krob G., Braun A., Kuhnle U. True hermaphroditism: geographical distribution, clinical findings, chromosomes and gonadal histology. Eur. J. Pediatr. 1994, 153(1):2-10.
27. Hadjiathanasiou C.G., et al. True hermaphroditism: genetic variants and clinical management. J. Pediatr. 1994, 125(5 Pt 1):738-744.
28. Boucekkine C., et al. Clinical and anatomical spectrum in XX sex reversed patients. Relationship to the presence of Y specific DNA-sequences. Clin, Endocrinol. (Oxf.) 1994, 40(6):733-742.
29. Berkovitz G.D., et al. The role of the sex-determining region of the Y chromosome (SRY) in the etiology of 46,XX true hermaphroditism. Hum. Genet. 1992, 88(4):411-416.
30. Damiani D., et al. True hermaphroditism: clinical aspects and molecular studies in 16 cases. Eur. J. Endocrinol. 1997, 136(2):201-204.
31. Abbas N., et al. Familial case of 46,XX male and 46,XX true hermaphrodite associated with a paternal-derived SRY-bearing X chromosome. C. R. Acad. Sci. III 1993, 316(4):375-383.
32. Huang B., et al. Autosomal XX sex reversal caused by duplication of SOX9. Am. J. Med. Genet. 1999, 87(4):349-353.
33. Rey R.A., et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimullerian hormone measurement. J. Clin. Endocrinol. Metab. 1999, 84(2):627-631.
34. Jimenez A.L., et al. Partially deleted SRY gene confined to testicular tissue in a 46,XX true hermaphrodite without SRY in leukocytic DNA. Am. J. Med. Genet. 2000, 93(5):417-420.
35. Ortenberg J., et al. SRY gene expression in the ovotestes of XX true hermaphrodites. J. Urol. 2002, 167(4):1828-1831.
36. Eiben B., et al. A cytogenetic study directly from chorionic villi of 140 spontaneous abortions. Hum. Genet. 1987, 77(2):137-141.
37. Stochholm K., et al. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J. Clin. Endocrinol. Metab. 2006, 91(10):3897-3902.
38. Reynaud K., et al. Number of ovarian follicles in human fetuses with the 45,X karyotype. Fertil. Steril. 2004, 81(4):1112-1119.
39. Weiss L. Additional evidence of gradual loss of germ cells in the pathogenesis of streak ovaries in Turner's syndrome. J. Med. Genet. 1971, 8(4):540-544.
40. Ferguson-Smith M.A. Karyotype-phenotype correlations in gonadal dysgenesis and their bearing on the pathogenesis of malformations. J. Med. Genet. 1965, 39:142-155.
41. Pasquino A.M., et al. Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. J. Clin. Endocrinol. Metab. 1997, 82(6):1810-1813.
42. Lue Y., et al. XXY male mice: an experimental model for Klinefelter syndrome. Endocrinology 2001, 142(4):1461-1470.
43. Thomas N.S., Hassold T.J. Aberrant recombination and the origin of Klinefelter syndrome. Hum. Reprod. Update 2003, 9(4):309-317.
44. Eskenazi B., et al. Sperm aneuploidy in fathers of children with paternally and maternally inherited Klinefelter syndrome. Hum. Reprod. 2002, 17(3):576-583.
45. Bojesen A., Juul S., Gravholt C.H. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J. Clin. Endocrinol. Metab. 2003, 88(2):622-626.
46. Robinson A., de la Chapelle A. Sex chromosome abnormalities. Emery and Rimoin's Principles and Practice of Medical Genetics 1996, Churchill Livingstone. E.A. Rimoin's (Ed.).
47. Lanfranco F., et al. Klinefelter's syndrome. Lancet 2004, 364(9430):273-283.
48. Bogatcheva N.V., Agoulnik A.I. INSL3/LGR8 role in testicular descent and cryptorchidism. Reprod. Biomed. Online 2005, 10(1):49-54.
49. New M.I., Rapaport R. The Adrenal Cortex. Pediatric Endocrinology 1996, 282-314. W.B. Saunders Co. M.A. Sperling (Ed.).
50. New M.I. Inborn errors of adrenal steroidogenesis. Mol. Cell Endocrinol. 2003, 211(1-2):75-83.
51. Peter M. Congenital adrenal hyperplasia: 11beta-hydroxylase deficiency. Semin. Reprod. Med. 2002, 20(3):249-254.
52. Peterson R.E., et al. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N. Engl. J. Med. 1985, 313(19):1182-1191.
53. Shackleton C., et al. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am. J. Med. Genet. 2004, 129A(2):105-112.
54. Arlt W., et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004, 363(9427):2128-2135.
55. Scott R.R., Miller W.L. Genetic and clinical features of P450 oxidoreductase deficiency. Horm. Res. 2008, 69(5):266-275.
56. Tajima T., et al. Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J. Clin. Endocrinol. Metab. 2001, 86(8):3820-3825.
57. Katsumata N., et al. Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J. Clin. Endocrinol. Metab. 2002, 87(8):3808-3813.
58. Stocco D.M. Clinical disorders associated with abnormal cholesterol transport: mutations in the steroidogenic acute regulatory protein. Mol. Cell Endocrinol. 2002, 191(1):19-25.
59. Fujieda K., et al. Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita. J. Steroid. Biochem. Mol. Biol. 2003, 85(2-5):483-489.
60. Fujieda K., et al. Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. J. Clin. Invest. 1997, 99(6):1265-1271.
61. Peterson R.E., et al. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am. J. Med. 1977, 62(2):170-191.
62. Imperato-McGinley J., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J. Clin. Endocrinol. Metab. 1992, 75(4):1022-1026.
63. Imperato-McGinley J. 5 Alpha-reductase-2 deficiency and complete androgen insensitivity: lessons from nature. Adv Exp Med Biol 2002, 511:121-131. discussion 131-134.
64. Saenger P., Goldman A.S., Levine L.S., Korth-Schutz S., Mvecke E.C., Katsumata M., Doberne Y., New M.I. Prepubertal diagnosis of steroid 5 alpha-reductase deficiency. J. Clin. Endocrinol. Metab. 1978, 46(4):627-634.
65. Galli-Tsinopoulou A., et al. A novel point mutation in the hormone binding domain of the androgen receptor associated with partial and minimal androgen insensitivity syndrome. J. Pediatr. Endocrinol. Metab. 2003, 16(2):149-154.
66. Pinsky L., et al. Human minimal androgen insensitivity with normal dihydrotestosterone-binding capacity in cultured genital skin fibroblasts: evidence for an androgen-selective qualitative abnormality of the receptor. Am. J. Hum. Genet. 1984, 36(5):965-978.
67. Bevan C.L., Hughes I.A., Patterson M.N. Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome. J. Steroid. Biochem. Mol. Biol. 1997, 61(1-2):19-26.
68. Brinkmann A.O. Molecular basis of androgen insensitivity. Mol. Cell Endocrinol. 2001, 179(1-2):105-109.
69. Sultan C., et al. Disorders of androgen action. Semin. Reprod. Med. 2002, 20(3):217-228.
70. Gottlieb B., et al. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 2004, 23(6):527-533.
71. Rutgers J.L., Scully R.E. The androgen insensitivity syndrome (testicular feminization): a clinicopathologic study of 43 cases. Int. J. Gynecol. Pathol. 1991, 10(2):126-144.
72. Mazur T. Gender dysphoria and gender change in androgen insensitivity or micropenis. Arch. Sex Behav. 2005, 34(4):411-421.
73. Brown T.R., Migeon C.J. Cultured human skin fibroblasts: a model for the study of androgen action. Mol. Cell Biochem. 1981, 36(1):3-22.
74. Ris-Stalpers C., et al. A practical approach to the detection of androgen receptor gene mutations and pedigree analysis in families with X-linked androgen insensitivity. Pediatr. Res. 1994, 36(2):227-234.
75. Richter-Unruh A., et al. Leydig cell hypoplasia: cases with new mutations, new polymorphisms and cases without mutations in the luteinizing hormone receptor gene. Clin. Endocrinol. (Oxf.) 2002, 56(1):103-112.
76. Wu S.M., et al. Luteinizing hormone receptor mutations in disorders of sexual development and cancer. Front Biosci. 2000, 5:D343-D352.
77. Martens J.W., et al. A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: correlation between receptor activity and phenotype. Mol. Endocrinol. 1998, 12(6):775-784.
78. Gromoll J., et al. Male hypogonadism caused by homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: differential action of human chorionic gonadotropin and LH. J. Clin. Endocrinol. Metab. 2000, 85(6):2281-2286.
79. Latronico A.C., et al. Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys: a novel constitutively activating mutation in the first transmembrane helix. J. Clin. Endocrinol. Metab. 2000, 85(12):4799-4805.
80. Latronico A.C. Naturally occurring mutations of the luteinizing hormone receptor gene affecting reproduction. Semin. Reprod. Med. 2000, 18(1):17-20.
81. Carel J.C., Leger J. Clinical practice. Precocious puberty. N. Engl. J. Med. 2008, 358(22):2366-2377.
82. Latronico A.C., et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N. Engl. J. Med. 1996, 334(8):507-512.
83. Latronico A.C., et al. A homozygous microdeletion in helix 7 of the luteinizing hormone receptor associated with familial testicular and ovarian resistance is due to both decreased cell surface expression and impaired effector activation by the cell surface receptor. Mol. Endocrinol. 1998, 12(3):442-450.
84. Toledo S., et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46,XX female. J. Clin. Endocrinol. Metab. 1996, 81(11):3850-3854.
85. Bruysters M., et al. A new LH receptor splice mutation responsible for male hypogonadism with subnormal sperm production in the propositus, and infertility with regular cycles in an affected sister. Hum. Reprod. 2008, 23(8):1917-1923.
86. Latronico A.C., Arnhold I.J. Inactivating mutations of LH and FSH receptors - from genotype to phenotype. Pediatr. Endocrinol. Rev. 2006, 4(1):28-31.
87. Chae H.D., et al. Ovarian hyperstimulation syndrome complicating a spontaneous singleton pregnancy: a case report. J. Assist. Reprod. Genet. 2001, 18(2):120-123.
88. Smits G., et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N. Engl. J. Med. 2003, 349(8):760-766.
89. Vasseur C., et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N. Engl. J. Med. 2003, 349(8):753-759.
90. Aittomaki K., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995, 82(6):959-968.
91. Layman L.C., et al. The Finnish follicle-stimulating hormone receptor gene mutation is rare in North American women with 46,XX ovarian failure. Fertil. Steril. 1998, 69(2):300-302.
92. Christin-Maitre S., et al. Genes and premature ovarian failure. Mol. Cell Endocrinol. 1998, 145(1-2):75-80.
93. Matthews C.H., et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat. Genet. 1993, 5(1):83-86.
94. Beyribey S., et al. Persistent Mullerian duct syndrome. Scand. J. Urol. Nephrol. 1993, 27(4):563-565.
95. Josso N., et al. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum. Reprod. Update 2005, 11(4):351-356.
96. Josso N., et al. Clinical aspects and molecular genetics of the persistent Mullerian duct syndrome. Clin. Endocrinol. (Oxf.) 1997, 47(2):137-144.
97. Koksal S., et al. Persistent Mullerian duct syndrome. Br. J. Clin. Pract. 1995, 49(5):276-277.
98. Lang-Muritano M., et al. A novel mutation in the anti-Mullerian hormone gene as cause of persistent Mullerian duct syndrome. Eur. J. Pediatr. 2001, 160(11):652-654.
99. Berkmen F. Persistent Mullerian duct syndrome with or without transverse testicular ectopia and testis tumours. Br. J. Urol. 1997, 79(1):122-126.
100. Ito Y., et al. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc. Natl. Acad. Sci. USA 1993, 90(24):11673-11677.
101. Shozu M., et al. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J. Clin. Endocrinol. Metab. 1991, 72(3):560-566.
102. Herrmann B.L., et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 2002, 87(12):5476-54784.
103. Mullis E., et al. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J. Clin. Endocrinol. Metab. 1997, 82(6):1739-1745.
104. Conte F.A., et al. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J. Clin. Endocrinol. Metab. 1994, 78(6):1287-1292.
105. Carreau S., et al. Aromatase expression and role of estrogens in male gonad: a review. Reprod. Biol. Endocrinol. 2003, 1(1):35.
106. Rochira V., et al. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol. Cell Endocrinol. 2002, 193(1-2):19-28.
107. Belgorosky A., et al. Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterozygote for two new point mutations of the CYP19 gene. J. Clin. Endocrinol. Metab. 2003, 88(11):5127-5131.
108. Nelson K.G., Goldenberg R.L. Sex hormones and congenital malformations: a review. J. Med. Assoc. State Ala. 1977, 46(11):31.
109. Coenen C.M., et al. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives. Int. J. Fertil. Menopausal. Stud. 1995, 40(Suppl. 2):92-97.
110. Ziaei S., et al. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route. Contraception 2002, 65(5):329-331.
111. Joshi R., Dunaif A. Ovarian disorders of pregnancy. Endocrinol. Metab. Clin. North Am. 1995, 24(1):153-169.